Search

Kim C Quon

from Seattle, WA
Age ~58
Get Report
Also known as:
Kim Qoun
Phone and address:
1711 NE Naomi Pl, Seattle, WA 98115
Related to:
Mariska S Kemna, 56Day W Quon
Connected to:
Anthony F Quon, 73Guida J Quon, 82Jeff Quon, 125Marilyn M Quon, 93Marissa C Quon, 34Markus C Quon, 52Robert D Quon, 61Rodney F Quon, 74Ryan S Quon, 37Tiffany A Quon, 37

Kim Quon Phones & Addresses

  • 1711 NE Naomi Pl, Seattle, WA 98115
  • Twisp, WA
  • Tacoma, WA
  • Belmont, CA
  • 1162 Clark Way, Palo Alto, CA 94304 (650) 328-2248
  • Encinitas, CA
  • Del Mar, CA
  • San Francisco, CA
  • San Diego, CA
  • La Jolla, CA

Work

Position: Clerical/White Collar

Education

Degree: High school graduate or higher

Resumes

Resumes

Kim Quon Photo 1

Principal - Architect

View page
Location:
San Diego, CA
Industry:
Architecture & Planning
Work:
Kim Quon Architect
Principal - Architect
Kim Quon Architect
Design-Build Manager Sub-Consultant
Hal Hays Construction, Inc. Nov 2011 - Feb 2013
Design-Build Manager
Straub Construction, Inc. May 2011 - Nov 2011
Design Build Manager
Macro-Z-Technology Oct 2009 - May 2011
Director of Architecture
Education:
California Polytechnic State University - San Luis Obispo 1973 - 1978
Bachelors, Bachelor of Science, Architectural Engineering Lowell High School 1970 - 1973
Skills:
Leed
Construction
Construction Management
Design Build
Submittals
Leed Ap
Value Engineering
Architecture
Bim
Green Building
Renovation
Contractors
Mixed Use
Project Bidding
Project Estimation
Contract Management
Project Planning
Revit
Concrete
Feasibility Studies
Process Scheduler
Autocad
Change Orders
Proposal Writing
Tenant Improvement
Sustainability
Contract Negotiation
Construction Drawings
Comprehensive Planning
Architectures
Civil Engineering
Design Management
Sustainable Design
Residential Homes
Entitlements
Design Research
Cpm Scheduling
Subcontracting
Pre Construction
Team Building
Architectural Design
Building Codes
Ms Project
Primavera P6
Constructability
Site Planning
Interests:
Human Rights
Certifications:
Leed Ap
Usgbc
Kim Quon Photo 2

Principal

View page
Location:
Seattle, WA
Industry:
Biotechnology
Work:
Ravenna Biotherapeutics
Principal
Amgen Feb 2013 - Dec 2014
Scientific Director
Amgen Oct 1, 2004 - Feb 2013
Scientist and Senior Scientist and Principal Scientist
Gnf 2002 - 2004
Principal Investigator and Group Leader
Education:
Stanford University School of Medicine 1989 - 1996
Stanford University School of Medicine
Skills:
Drug Discovery
Lifesciences
Cell Biology
Drug Development
Biotechnology
Assay Development
Biochemistry
Cell
High Throughput Screening
Cell Culture
Molecular Biology
Antibodies
Genomics
Biopharmaceuticals

Publications

Us Patents

Fusion Proteins In Cancer

View page
US Patent:
20130095111, Apr 18, 2013
Filed:
Jun 28, 2011
Appl. No.:
13/805321
Inventors:
Kim Coign Quon - Seattle WA, US
Gene Cutler - San Francisco CA, US
Jennifer Joy Kordich - Sammamish WA, US
Assignee:
AMGEN INC. - Thousand Oaks CA
International Classification:
A61K 47/48
G01N 33/68
C07K 16/30
US Classification:
4241391, 5303879, 5303917, 5303873, 4241781, 435 723, 435 611, 435 614, 435375
Abstract:
The present invention provides fusion proteins expressed by cancer cells, antibodies and other antigen-binding agents that specifically bind to the fusion proteins, and compositions and methods for using the antibodies and other antigen-binding agents to detect, characterize, and treat cancer.

Anti-Mct1 Antibodies And Uses Thereof

View page
US Patent:
20190263931, Aug 29, 2019
Filed:
Jan 4, 2019
Appl. No.:
16/240499
Inventors:
- Lebanon NH, US
- Thousand Oaks CA, US
Kimberly P. Shigenaka - Seattle WA, US
Marcia Gordon - Seattle WA, US
Kim Quon - Seattle WA, US
Philipe Gobeil - Toronto, CA
Catherine Carriere - Lebanon NH, US
Sergey Seregin - Lebanon NH, US
Yong Wang - Mountain View CA, US
Raphael D. Levy - Redwood City CA, US
Jordon K. Wang - San Carlos CA, US
International Classification:
C07K 16/40
A61P 3/10
A61P 37/06
C07K 16/28
A61K 47/68
G01N 33/50
Abstract:
This invention generally pertains to antibodies and antigen-binding fragments thereof, e.g., humanized, chimeric, and human antibodies and antigen-binding fragments thereof, and fusion proteins, compositions containing such antibodies and antigen-binding fragments thereof and fusion proteins, wherein such antibodies and antigen-binding fragments thereof and fusion proteins specifically bind to MCT1, e.g., human or non-human MCT1 and antagonize, inhibit or block one or more MCT1-associated functions in vitro and/or in vivo. The invention also relates to therapeutic and diagnostic uses of these anti-MCT1 antibodies, antigen-binding fragments, fusion proteins and compositions containing optionally wherein these anti-MCT1 antibodies, antigen-binding fragments, fusion proteins and compositions containing are used in therapeutic regimens that further include the administration of other therapeutic agents, e.g., mitochondrial inhibitors and/or biguanides or small molecule MCT1 inhibitors.
Control profile
Kim C Quon from Seattle, WA, age ~58 Get Report